Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities, J Rheumatol Suppl, vol.85, pp.2-10, 2010. ,
Understanding human autoimmunity and autoinflammation through transcriptomics, Annu Rev Immunol, vol.35, pp.337-70, 2017. ,
Environmental risk factors for inflammatory bowel diseases: a review, Digest Dis Sci, vol.60, pp.290-298, 2015. ,
Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses, Lancet Neurol, vol.14, pp.263-73, 2015. ,
Genetic insights into common pathways and complex relationships among immune-mediated diseases, Nat Rev Genet, vol.14, pp.661-73, 2013. ,
Pervasive sharing of genetic effects in autoimmune disease, PLoS Genet, vol.7, 2011. ,
Genetics of infectious and inflammatory diseases: overlapping discoveries from association and exome-sequencing studies, Annu Rev Immunol, vol.35, pp.1-30, 2017. ,
The genomic landscape of human immune-mediated diseases, J Hum Genet, vol.60, pp.675-81, 2015. ,
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, International Multiple Sclerosis Genetics Consortium, vol.45, pp.1353-60, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-02565210
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, Multiple Sclerosis Genetics Consortium, vol.476, pp.214-223, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00996686
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease, Nature, vol.491, pp.119-143, 2012. ,
Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors, J Rheumatol, vol.28, pp.2667-73, 2001. ,
Autoimmune diseases cooccurring within individuals and within families: a systematic review, Epidemiology, vol.17, pp.202-219, 2006. ,
How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy, Nat Med, vol.19, pp.822-826, 2013. ,
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin, Nature, vol.312, pp.724-733, 1984. ,
The TNF and TNF receptor superfamilies: integrating mammalian biology, Cell, vol.104, pp.487-501, 2001. ,
Signalling pathways of the TNF superfamily: a double-edged sword, Nat Rev Immunol, vol.3, pp.745-56, 2003. ,
Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B, Mol Cell Biol, vol.10, pp.1498-506, 1990. ,
Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor, Proc Natl Acad Sci, vol.83, pp.3949-53, 1986. ,
Identity of differentiation inducing factor and tumour necrosis factor, Nature, vol.323, pp.338-378, 1986. ,
Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon, J Exp Med, vol.164, pp.1206-1231, 1986. ,
Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1, J Immunol, vol.139, pp.2970-2976, 1987. ,
Effect of tumor necrosis factor alpha on mitogen-activated human B cells, J Exp Med, vol.166, pp.786-91, 1987. ,
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1, J Exp Med, vol.163, pp.1433-50, 1986. ,
Tumor necrosis factor-? is required in the protective immune response against mycobacterium tuberculosis in mice, Immunity, vol.2, pp.561-72, 1995. ,
TNF-receptors: from mediators of cell death and inflammation to therapeutic giants -past, present and future, Cytokine Growth Factor Rev, vol.25, pp.453-72, 2014. ,
A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF, Cell, vol.53, pp.45-53, 1988. ,
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha, Nature, vol.385, pp.733-739, 1997. ,
The transmembrane form of tumor-necrosis-factor is the prime activating ligand of the 80 Kda tumor-necrosis-factor receptor, Cell, vol.83, pp.793-802, 1995. ,
Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction, J Biol Chem, vol.277, pp.44155-63, 2002. ,
Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligandmediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages, J Biol Chem, vol.276, pp.31906-31918, 2001. ,
TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60, J Immunol, vol.161, pp.3136-3178, 1998. ,
Signal transduction by tumor necrosis factor receptors, Cell Signal, vol.24, pp.1297-305, 2012. ,
TNF biology, pathogenic mechanisms and emerging therapeutic strategies, Nat Rev Rheumatol, vol.12, pp.49-62, 2016. ,
Regulation of tumour necrosis factor signalling: live or let die, Nat Rev Immunol, vol.15, pp.362-74, 2015. ,
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation, Science, vol.281, pp.1680-1683, 1998. ,
Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles, Immunity, vol.21, pp.415-443, 2004. ,
Programmed necrosis in the cross talk of cell death and inflammation, Annu Rev Immunol, vol.33, pp.79-106, 2015. ,
Necroptosis and its role in inflammation, Nature, vol.517, pp.311-331, 2015. ,
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis, Nature, vol.488, pp.508-519, 2012. ,
Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses, J Exp Med, vol.172, pp.1019-1042, 1990. ,
Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation, J Immunol, vol.160, pp.3152-62, 1998. ,
Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2, EMBO J, vol.16, pp.1080-92, 1997. ,
TNFalpha induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination, EMBO J, vol.24, pp.1886-98, 2005. ,
Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2, Tissue Antigens, vol.54, pp.585-91, 1999. ,
Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians, Arthritis Rheumat, vol.44, pp.61-66, 2001. ,
Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity, Arthritis Rheumat, vol.46, pp.2039-2083, 2002. ,
URL : https://hal.archives-ouvertes.fr/hal-02084357
The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression, J Biol Chem, vol.280, pp.5994-6004, 2005. ,
Phase II clinical trial of high-dose recombinant human tumor necrosis factor, Cancer Chemother Pharmacol, vol.24, pp.391-393, 1989. ,
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin, Science, vol.229, pp.869-71, 1985. ,
Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia, Nature, vol.330, pp.662-666, 1987. ,
Development of anti-TNF therapy for rheumatoid arthritis, Nat Rev Immunol, vol.2, pp.364-71, 2002. ,
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab, Arthritis Rheum, vol.43, pp.1346-52, 2000. ,
Anti-tumour necrosis factor ? therapy for ankylosing spondylitis: international experience, Ann Rheum Dis, vol.61, pp.51-60, 2002. ,
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha, N Engl J Med, vol.346, pp.1349-56, 2002. ,
American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, Arthritis Rheumatol, vol.68, pp.282-98, 2016. ,
New evidence on the management of spondyloarthritis, Nat Rev Rheumatol, vol.12, pp.282-95, 2016. ,
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?, Ann Rheum Dis, vol.62, pp.829-863, 2003. ,
Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer, Bmj, vol.352, p.472, 2016. ,
An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors, J Eur Acad Dermatol Venereol, vol.29, pp.752-60, 2015. ,
Differential expression and response to anti-TNF? treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis, J Pathol, vol.206, pp.17-27, 2005. ,
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis, Lancet, vol.344, pp.1105-1115, 1994. ,
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody, Mol Immunol, vol.30, issue.93, p.90106, 1993. ,
The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo, Cytokine, vol.7, pp.15-25, 1995. ,
Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies, Immunotherapy, vol.2, pp.453-60, 2010. ,
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, vol.2, pp.253-262, 1999. ,
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor ? agents, Inflamm Bowel Dis, vol.13, pp.1323-1355, 2007. ,
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor, Clin Immunol, vol.131, pp.308-324, 2009. ,
Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha, Gastroenterology, vol.126, pp.934-939, 2004. ,
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease, Gastroenterology, vol.124, pp.1774-85, 2003. ,
Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor ?-expressing cells: comparison among infliximab, etanercept, and adalimumab, Arthritis Rheum, vol.58, pp.1248-57, 2008. ,
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry, Ann Rheum Dis, vol.71, pp.1134-1176, 2012. ,
Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study), Arthritis Res Ther, vol.16, p.467, 2014. ,
True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?, Ann Rheum Dis, vol.63, pp.1344-1350, 2004. ,
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, vol.337, pp.1029-1064, 1997. ,
Etanercept for active Crohn's disease: a randomized, doubleblind, placebo-controlled trial, Gastroenterology, vol.121, pp.1088-94, 2001. ,
The risk of herpes zoster in the anti-TNF-alpha era: a case report and review of the literature, J Dermatol Case Rep, vol.7, pp.1-4, 2013. ,
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR), Ann Rheum Dis, vol.69, pp.522-530, 2010. ,
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry, Arthritis Rheum, vol.60, pp.1884-94, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00618680
Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis, Rheumatology, vol.47, pp.897-900, 2008. ,
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions, Cytokine, vol.7, pp.251-260, 1995. ,
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review, Pharmacol Ther, vol.117, pp.244-79, 2008. ,
Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint, PLoS ONE, vol.5, p.12516, 2010. ,
Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression, Rheumatology, vol.49, pp.2264-72, 2010. ,
Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-? therapy, Arthritis Res Ther, vol.13, 2011. ,
Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients, Clin Vacc Immunol, vol.18, pp.1077-82, 2011. ,
Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis, J Clin Immunol, vol.31, pp.596-605, 2011. ,
In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis, J Rheumatol, vol.39, pp.830-835, 2012. ,
Incomplete response of inflammatory arthritis to TNF? blockade is associated with the Th17 pathway, Ann Rheum Dis, vol.71, pp.1741-1749, 2012. ,
Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy, Clin Dev Immunol, p.808724, 2012. ,
Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-? therapy, J Clin Immunol, vol.33, pp.151-61, 2013. ,
The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study, Clin. Rheumatol, vol.33, pp.175-85, 2014. ,
TNF-alpha blockade induces IL-10 expression in human CD4+ T cells, Nat Commun, vol.5, p.3199, 2014. ,
Antitumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis, Clin Exp Immunol, vol.181, pp.401-407, 2015. ,
Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response, J Clin Immunol, vol.35, pp.550-557, 2015. ,
Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis, Arthritis Res Ther, vol.18, p.303, 2016. ,
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy, J Exp Med, vol.200, pp.277-85, 2004. ,
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta, J Exp Med, vol.204, pp.33-42, 2007. ,
Anti-TNF-alpha therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis, Cell Immunol, vol.279, pp.25-34, 2012. ,
Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy, Arthritis Rheumat, vol.64, pp.3129-3167, 2012. ,
Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis, J Exp Med, vol.213, pp.1241-53, 2016. ,
Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks, J Immunol, vol.180, pp.688-92, 2008. ,
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor, Arthritis Res Ther, vol.11, 2009. ,
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor, Arthritis Res Ther, vol.13, 2011. ,
Anti-TNF treatment blocks the induction of T cell-dependent humoral responses, Ann Rheum Dis, vol.72, pp.1037-1080, 2013. ,
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment, Clin Exp Immunol, vol.177, pp.234-277, 2014. ,
Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity, Arthritis Rheumatol, vol.66, pp.2037-2083, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02191567
Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis, Arthritis Rheumatol, vol.66, pp.2590-600, 2014. ,
Increased frequency of circulating CD19+CD24hiCD38hi B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) naïve for biological agents, PLoS ONE, vol.12, p.180726, 2017. ,
Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-? therapy in children with rheumatic diseases: a cross-sectional study, Vaccine, vol.34, pp.1304-1315, 2016. ,
Defective function of CD24(+)CD38(+) regulatory B cells in ankylosing spondylitis, DNA Cell Biol, vol.35, pp.88-95, 2016. ,
Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis, Arthritis Res Ther, vol.19, p.33, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02544267
Regulatory B cells in rheumatoid arthritis: alterations in patients receiving anti-TNF therapy, Clin Immunol, vol.184, pp.63-72, 2017. ,
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17-and IFNgamma-producing T cells, Clin Immunol, vol.184, pp.33-41, 2017. ,
Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis, Clin Exp Rheumatol, vol.24, pp.31-38, 2006. ,
Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas, J Autoimmunity, vol.80, pp.56-64, 2017. ,
Chemotaxis of Vdelta2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis, Ann Rheum Dis, vol.76, pp.2075-84, 2017. ,
IL-22-and GM-CSF-expressing but not IL-17A-expressing group 3 innate lymphoid cells are expanded in the inflamed spondyloarthritis joint, Arthritis Rheumatol, vol.71, pp.392-402, 2019. ,
CD16+ blood monocytes and joint inflammation in rheumatoid arthritis, Arthritis Rheumat, vol.46, pp.2578-86, 2002. ,
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, vol.170, pp.36-46, 2012. ,
CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence, Arthritis Res Ther, vol.15, p.139, 2013. ,
Interleukin-6 and tumour necrosis factor-alpha differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis, Cytokine, vol.68, pp.65-73, 2014. ,
In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis, J Transl Med, vol.13, p.256, 2015. ,
Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis, RMD Open, vol.2, p.79, 2016. ,
M2 polarization of monocytes in ankylosing spondylitis and relationship with inflammation and structural damage, Acta Pathol Microbiol Immunol Scand, vol.125, pp.1070-1075, 2017. ,
Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis, Arthritis Rheum, vol.42, pp.2166-73, 1999. ,
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab, Arthritis Rheum, vol.48, pp.780-90, 2003. ,
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept, Ann Rheumat Dis, vol.62, pp.561-565, 2003. ,
Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-gamma-producing NK cell and regulatory T cell subsets, Immunobiology, vol.216, pp.1256-63, 2011. ,
Tcell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy, Mediators Inflamm, p.6894374, 2017. ,
Regulation of cytokines, cytokine inhibitors, and acutephase proteins following anti-TNF-alpha therapy in rheumatoid arthritis, J Immunol, vol.163, pp.1521-1529, 1999. ,
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis, Arthritis Rheumat, vol.43, pp.38-47, 2000. ,
Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis, Ann Rheumat Dis, vol.60, pp.660-669, 2001. ,
Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis, Clin Exp Rheumatol, vol.24, pp.529-562, 2006. ,
Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis, Rheumatol Int, vol.28, pp.137-180, 2007. ,
Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis, Ann Rheum Dis, vol.66, pp.1334-1342, 2007. ,
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis, Clin Exp Immunol, vol.153, pp.188-95, 2008. ,
Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblastlike synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs, J Rheumatol, vol.36, p.132, 2009. ,
Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis, J Rheumatol, vol.36, pp.1158-65, 2009. ,
Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents, Eur Cytokine Netw, vol.20, pp.88-93, 2009. ,
Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis, J Rheumatol, vol.37, pp.1073-1077, 2010. ,
The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients, Rheumatol Int, vol.30, pp.1553-1560, 2010. ,
Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues, Clin Immunol, vol.139, pp.164-76, 2011. ,
Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis, BMC Musculoskelet Disorders, vol.13, p.191, 2012. ,
Interleukin-1beta measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis, Rheumatology, vol.51, pp.1639-1682, 2012. ,
Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production, J Interfer Cytokine Res, vol.33, pp.398-401, 2013. ,
CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity', Arthritis Res Ther, vol.16, p.434, 2014. ,
Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis, Rheumatol Int, vol.35, pp.71-80, 2015. ,
Anti-TNF-alpha therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients, Rheumatol Int, vol.35, pp.2069-78, 2015. ,
IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients, Arthritis Res Ther, vol.18, p.52, 2016. ,
Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study, Arthritis Res Ther, vol.10, pp.1-7, 2016. ,
The impact of disease activity and tumour necrosis factor-alpha inhibitor therapy on cytokine levels in juvenile idiopathic arthritis, Clin Exp Immunol, vol.184, pp.308-325, 2016. ,
Increased pretreatment serum IFN-?/a ratio predicts nonresponse to tumour necrosis factor a inhibition in rheumatoid arthritis, Ann Rheumat Dis, vol.75, pp.1757-62, 2016. ,
Response to treatment with TNFa inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF+ T lymphocytes, Clin Rev Allergy Immunol, vol.53, pp.265-76, 2017. ,
Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis, Nat Commun, vol.8, pp.1-11, 2017. ,
Increased frequency of peripheral B and T cells expressing granulocyte monocyte colony-stimulating factor in rheumatoid arthritis patients, Front Immunol, vol.8, 1967. ,
TNF? in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases, Cytokine, vol.101, pp.4-13, 2018. ,
Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review, Arthritis Res Ther, vol.20, p.229, 2018. ,
Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling, J Exp Med, vol.185, pp.1573-84, 1997. ,
TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues, Blood, vol.109, pp.4328-4335, 2007. ,
A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage, Nat Med, vol.13, pp.139-184, 2007. ,
Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells, Eur J Immunol, vol.38, pp.2512-2539, 2008. ,
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages, Nat Immunol, vol.6, pp.1123-1155, 2005. ,
Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17, Arthritis Rheum, vol.56, pp.1145-51, 2007. ,
Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma, Arthritis Res Ther, vol.11, 2009. ,
Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis, Ann Rheum. Dis, vol.63, pp.681-688, 2004. ,
Influence of therapy with chimeric monoclonal tumour necrosis factoralpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients, Rheumatology, vol.42, pp.541-549, 2003. ,
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells, J Exp Med, vol.205, pp.2491-2498, 2008. ,
Plasminogen activator/plasmin system in arthritis and inflammation: friend or foe?, Arthritis Rheum, vol.58, pp.645-653, 2008. ,
Novel therapeutic targets in axial spondyloarthritis, Curr Treatm Opt Rheumatol, vol.4, pp.174-82, 2018. ,
The biology of GM-CSF: regulation of production and interaction with its receptor, Int J Cell Cloning, vol.8, pp.35-44, 1990. ,
Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis, Ann Rheum Dis, vol.75, pp.899-907, 2016. ,
Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis, Ann Rheum Dis, vol.74, pp.1924-1954, 2015. ,
Th1 is the predominant helper T cell subset that produces GM-CSF in the joint of rheumatoid arthritis. RMD Open, vol.3, p.487, 2017. ,
Mavrilimumab, a fully human granulocyte-macrophage colonystimulating factor receptor ? monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis, Arthritis Rheumatol, vol.70, pp.679-89, 2018. ,
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis, Arthritis Rheum, vol.39, pp.1077-81, 1996. ,
Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls, Crit Rev Clin Lab Sci, vol.37, pp.131-82, 2000. ,
Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors, Rheumatology, vol.44, pp.172-177, 2005. ,
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model, J Exp Med, vol.204, pp.2803-2815, 2007. ,
CXC chemokines in angiogenesis, Cytokine Growth Factor Rev, vol.16, pp.593-609, 2005. ,
Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis?, Rheumatol Int, vol.27, pp.969-73, 2007. ,
Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells, Arthritis Res Ther, vol.19, p.142, 2017. ,
Gut microbiome in children with enthesitis-related arthritis in a developing country and the effect of probiotic administration, Clin Exp Immunol, vol.187, pp.480-489, 2017. ,
B Lymphocytes in rheumatoid arthritis and the effects of anti-TNF-? agents on B lymphocytes: a review of the literature, Clin Ther, vol.40, pp.1034-1079, 2018. ,
Advances in human B cell phenotypic profiling, Front Immunol, vol.3, p.302, 2012. ,
Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients Naïve for TNF blockers, PLoS ONE, vol.9, p.107086, 2014. ,
Disturbances in B-and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses, J Autoimmun, vol.29, pp.154-63, 2007. ,
The expanding family of regulatory B cells, Int Immunol, vol.27, pp.479-86, 2015. ,
CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation, Sci Transl Med, vol.5, pp.173-196, 2013. ,
Differences in binding and effector functions between classes of TNF antagonists, Cytokine, vol.45, pp.124-155, 2009. ,
Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity, Clin Immunol, vol.134, pp.113-133, 2010. ,
Ectopic lymphoid neogenesis in rheumatic autoimmune diseases, Nature reviews. Rheumatology, vol.13, pp.141-54, 2017. ,
Ectopic lymphoid structures: powerhouse of autoimmunity, Front Immunol, vol.7, p.430, 2016. ,
Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase, J Exp Med, vol.197, pp.1153-63, 2003. ,
TNFalpha-dependent development of lymphoid tissue in the absence of RORgammat(+) lymphoid tissue inducer cells, Mucos Immunol, vol.7, pp.602-616, 2014. ,
Chronic inflammation caused by lymphotoxin is lymphoid neogenesis, J Exp Med, vol.183, pp.1461-72, 1996. ,
Clinical significance of synovial lymphoid neogenesis and its reversal after antitumour necrosis factor alpha therapy in rheumatoid arthritis, Ann Rheumat Dis, vol.68, pp.751-757, 2009. ,
B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis, J Immunol, vol.181, pp.785-94, 2008. ,
Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues, Immunology, vol.147, pp.141-51, 2016. ,
Ectopic lymphoid structures support ongoing production of classswitched autoantibodies in rheumatoid synovium, PLoS Med, vol.6, p.1, 2009. ,
Ectopic germinal centers and IgG4-producing plasmacytes observed in synovia of HLA-B27+ ankylosing spondylitis patients with advanced hip involvement, Int J Rheumatol, p.316421, 2015. ,
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis, Ann Rheum Dis, vol.63, pp.665-70, 2004. ,
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study, Arthritis Res Ther, vol.13, 2011. ,
Erythrocyte sedimentation rate, Creactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis, Arthritis Rheumat, vol.61, pp.1484-90, 2009. ,
ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy, Reumatol Clin, vol.10, pp.204-213, 2014. ,
Body weight, gender and response to TNF-? blockers in axial spondyloarthritis, Rheumatology, vol.53, pp.875-81, 2014. ,
Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry, Rheumatology, vol.55, pp.659-68, 2016. ,
BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors, Ann Rheumat Dis, vol.70, pp.1375-81, 2011. ,
Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis, Arthritis Res Ther, vol.16, p.413, 2014. ,
MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, Ann Rheum Dis, vol.74, pp.499-505, 2015. ,
Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment, Arthritis Res Ther, vol.12, p.11, 2010. ,
Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept, Arthritis Res Ther, vol.10, p.50, 2008. ,
CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis, Clin Pharmacol Ther, vol.87, pp.311-332, 2010. ,
Cell-centred meta-analysis reveals baseline predictors of anti-TNF? non-response in biopsy and blood of patients with IB, Gut, vol.2018, pp.1-11, 2018. ,
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease, Nat Med, vol.23, pp.579-89, 2017. ,
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease, Nat Med, vol.20, pp.313-321, 2014. ,
Microbiota composition may predict anti-Tnf alpha response in spondyloarthritis patients: an exploratory study, Sci Rep, vol.8, p.5446, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01760163
Metabolic profiling predicts response to anti-tumor necrosis factor ? therapy in patients with rheumatoid arthritis, Arthritis Rheum, vol.65, pp.1448-56, 2013. ,
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol, vol.21, pp.2286-91, 1994. ,
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores, Ann Rheum Dis, vol.70, pp.47-53, 2011. ,
Spondyloarthritis: is it time to replace BASDAI with ASDAS?, Nat Rev Rheumatol, vol.9, pp.388-90, 2013. ,
Relative value of erythrocyte sedimentation rate and Creactive protein in assessment of disease activity in ankylosing spondylitis, J Rheumatol, vol.26, pp.980-984, 1999. ,
Acute-phase proteins and other systemic responses to inflammation, N Engl J Med, vol.340, pp.448-54, 1999. ,
Validity aspects of erythrocyte sedimentation rate and Creactive protein in ankylosing spondylitis: a literature review, J Rheumatol, vol.26, pp.966-70, 1999. ,
Predicting the outcome of ankylosing spondylitis therapy, Ann Rheumat Dis, vol.70, pp.973-81, 2011. ,
Predictors of response to anti-TNF-? therapy among patients with rheumatoid arthritis: results from the British Society for, Rheumatology Biologics Register. Rheumatology, vol.45, pp.1558-65, 2006. ,
Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis, J Rheumatol, vol.38, pp.1644-50, 2011. ,
Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis, Ann Rheumat Dis, vol.73, pp.1746-1754, 2014. ,
Identification of fungi with potential micotoxigenic in fish meals used for preparation, Mol Cell Biol, vol.23, pp.2564-76, 2003. ,
Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity, J Mol Biol, vol.359, pp.961-72, 2006. ,
Proinflammatory S100 proteins in arthritis and autoimmune disease, Arthritis Rheumat, vol.50, pp.3762-71, 2004. ,
Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis, Ann rheumat Dis, vol.67, pp.1750-1758, 2008. ,
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock, Nat Med, vol.13, pp.1042-1051, 2007. ,
The tolllike receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+T cells, Nat Med, vol.16, pp.713-720, 2010. ,
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheumat Dis, vol.76, pp.960-77, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01778213
Rheumatoid arthritis: biomarkers of response to TNF inhibition in RA, Nat Rev Rheumatol, vol.11, pp.446-454, 2015. ,
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy, Arthritis Rheumat, vol.62, pp.1849-61, 2010. ,
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort, Arthritis Rheumat, vol.64, pp.665-70, 2012. ,
Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis, Inflammation, vol.36, pp.279-84, 2013. ,
,
, Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis, PLoS Genet, vol.9, p.1003394, 2013.
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis, Nat Commun, vol.7, p.12460, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01420921
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, J Biol Chem, vol.278, pp.1910-1914, 2003. ,
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, vol.421, pp.744-752, 2003. ,
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J Exp Med, vol.201, pp.233-273, 2005. ,
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo, Nat Immunol, vol.10, pp.314-338, 2009. ,
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology, Nature, vol.464, pp.1371-1376, 2010. ,
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease, J Exp Med, vol.208, pp.1127-1160, 2011. ,
Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity, Immunity, vol.31, pp.331-372, 2009. ,
Enrichment of circulating interleukin-17-secreting interleukin-23 receptorpositive gamma/delta T cells in patients with active ankylosing spondylitis, Arthritis Rheum, vol.64, pp.1420-1429, 2012. ,
, IL-23 induces spondyloarthropathy by acting on ROR-gammat(+)
, CD8(-) entheseal resident T cells, CD3(+)CD4(-), vol.18, pp.1069-76, 2012.
Genetics of ankylosing spondylitisinsights into pathogenesis, Nat Rev Rheumatol, vol.12, pp.81-91, 2016. ,
Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis, Arthritis Rheum, vol.65, pp.1510-1531, 2013. ,
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans, PLoS ONE, vol.6, 2011. ,
Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses, Proc Natl Acad Sci, vol.108, pp.9560-9565, 2011. ,
Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression, Science, vol.343, p.1246949, 2014. ,
Approaches for establishing the function of regulatory genetic variants involved in disease, Genome Med, vol.6, p.92, 2014. ,
Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges, Proc Natl Acad Sci USA, vol.115, pp.488-97, 2018. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01721850
Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases, Annu Rev Med, vol.67, pp.337-53, 2016. ,
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides, Arthritis Rheum, vol.58, pp.2307-2324, 2008. ,
Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis, Arthritis Rheum, vol.60, pp.1647-56, 2009. ,
Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis, J Immunol, vol.186, pp.2672-80, 2011. ,
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, vol.382, pp.1705-1718, 2013. ,
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, N Engl J Med, vol.373, pp.978-91, 2015. ,
Secukinumab in plaque psoriasis-results of two phase 3 trials, N Engl J Med, vol.371, pp.326-364, 2014. ,
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, doubleblind, placebo-controlled, phase 3 trial, Lancet, vol.386, pp.1137-1183, 2015. ,
Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis, N Engl J Med, vol.373, pp.1329-1368, 2015. ,
Secukinumab in Crohn's Disease Study, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial, Gut, vol.61, pp.1693-700, 2012. ,
A randomized, Double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe crohn's disease, Am J Gastroenterol, vol.111, pp.727-765, 2015. ,
Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial Immunopathology without compromising systemic immune responses, Arthritis Rheumatol, vol.70, 1994. ,
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis, N Engl J Med, vol.356, pp.580-92, 2007. ,
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, vol.371, pp.1665-74, 2008. ,
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, vol.371, pp.726-732, 2008. ,
Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis, N Engl J Med, vol.362, pp.118-146, 2010. ,
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis, N Engl J Med, vol.376, pp.1551-60, 2017. ,
Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation, J Exp Med, vol.198, pp.1951-1958, 2003. ,
Interleukin-23 drives innate and T cell-mediated intestinal inflammation, J Exp Med, vol.203, pp.2473-83, 2006. ,
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6, J Clin Invest, vol.116, pp.1310-1316, 2006. ,
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, doubleblind, placebo-controlled phase 2 study, Lancet, vol.389, issue.17, pp.30570-30576, 2017. ,
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, N Engl J Med, vol.375, pp.1946-60, 2016. ,
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study, Ann Rheum Dis, vol.77, pp.1295-302, 2018. ,
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants, Nat Genet, vol.39, pp.1329-1366, 2007. ,
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci, Nat. Genet, vol.48, pp.510-518, 2016. ,
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci, International Genetics of Ankylosing Spondylitis Consortium, vol.45, pp.730-738, 2013. ,
IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis, Ann Rheum Dis, vol.75, pp.2124-2156, 2016. ,
The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling, Front Immunol, vol.9, p.1550, 2018. ,